Based on the structure of Coumarin and sulfonamide, Belma (5) designed a series of compounds and tested their abilities to inhibit the expression of CA I, CA II, CA IX, and CA XII in colon cancer cells. Here, CA9 is linked to malignant colon neoplasm.